Page 33 - JCTR-11-4

Journal of Clinical and
Translational Research Propranolol as a treatment for HCC

Virology. 2012;422(2):377-385. doi: 10.1523/JNEUROSCI.2574-04.2004
doi: 10.1016/j.virol.2011.11.009 34. Dobarro M, Orejana L, Aguirre N, Ramírez MJ. Propranolol
restores cognitive deficits and improves amyloid and Tau
23. Goossens N, Hoshida Y. Hepatitis C virus-induced pathologies in a senescence-accelerated mouse model.
hepatocellular carcinoma. Clin Mol Hepatol. Neuropharmacology. 2013;64:137-44.
2015;21(2):105-114.
doi: 10.1016/j.neuropharm.2012.06.047
doi: 10.3350/cmh.2015.21.2.105
35. Kao J, Luu B. Can propranolol prevent progression of
24. Yuan H, Xu R, Li S, et al. The malignant transformation of melanoma? JAAPA. 2019;32(6):1-5.
viral hepatitis to hepatocellular carcinoma: Mechanisms and
interventions. MedComm (2020). 2025;6(3):e70121. doi: 10.1097/01.JAA.0000558241.84003.91
doi: 10.1002/mco2.70121 36. Xie Y. Hepatitis B virus-associated hepatocellular carcinoma.
Adv Exp Med Biol. 2017;1018:11-21.
25. He Y, Staschke KA, Tan SL. HCV NS5A: A multifunctional
regulator of cellular pathways and virus replication. In: doi: 10.1007/978-981-10-5765-6_2
Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular 37. Storch CH, Hoeger PH. Propranolol for infantile
Biology. Norfolk (UK): Horizon Bioscience; 2006. haemangiomas: Insights into the molecular mechanisms of

26. Rebbani K, Tsukiyama-Kohara K. HCV-induced oxidative action. Br J Dermatol. 2010;163(2):269-274.
stress: Battlefield-winning strategy. Oxid Med Cell Longev. doi: 10.1111/j.1365-2133.2010.09848.x
2016;2016:7425628.
38. Ji Y, Li K, Xiao X, et al. Effects of propranolol on the
doi: 10.1155/2016/7425628 proliferation and apoptosis of hemangioma-derived
27. Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From endothelial cells. J Pediatr Surg. 2012;47(12):2216-2223.
inflammatory pathogenesis to anti-inflammatory/ doi: 10.1016/j.jpedsurg.2012.09.008
hepatoprotective therapy. World J Gastroenterol. 39. Wołowiec Ł, Grześk G, Osiak J, et al. Beta-blockers in
2018;24(47):5297-5311.
cardiac arrhythmias-Clinical pharmacologist’s point of view.
doi: 10.3748/wjg.v24.i47.5297 Front Pharmacol. 2022;13:1043714.
28. Zhao H, Wu L, Yan G, et al. Inflammation and tumor doi: 10.3389/fphar.2022.1043714
progression: Signaling pathways and targeted intervention. 40. Solernó LM, Sobol NT, Gottardo MF, et al. Propranolol blocks
Signal Transduct Target Ther. 2021;6(1):263.
osteosarcoma cell cycle progression, inhibits angiogenesis
doi: 10.1038/s41392-021-00658-5 and slows xenograft growth in combination with cisplatin-
based chemotherapy. Sci Rep. 2022;12(1):15058.
29. Zampino R, Marrone A, Restivo L, et al. Chronic HCV
infection and inflammation: Clinical impact on hepatic doi: 10.1038/s41598-022-18324-3
and extra-hepatic manifestations. World J Hepatol. 41. Fjæstad KY, Rømer AMA, Goitea V, et al. Blockade of beta-
2013;5(10):528-540. adrenergic receptors reduces cancer growth and enhances
doi: 10.4254/wjh.v5.i10.528 the response to anti-CTLA4 therapy by modulating the
tumor microenvironment. Oncogene. 2022;41(9):1364-1375.
30. Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell
metabolism: Oncogenic MYC in the driver’s seat. Signal doi: 10.1038/s41388-021-02170-0
Transduct Target Ther. 2020;5(1):124. 42. Pasquier E, Ciccolini J, Carre M, et al. Propranolol
doi: 10.1038/s41392-020-00235-2 potentiates the anti-angiogenic effects and anti-tumor
efficacy of chemotherapy agents: Implication in breast
31. Srinivasan AV. Propranolol: A 50-year historical perspective. cancer treatment. Oncotarget. 2011;2(10):797-809.
Ann Indian Acad Neurol. 2019;22(1):21-26.
doi: 10.18632/oncotarget.343
doi: 10.4103/aian.AIAN_201_18
43. Tu Z, Zhong Y, Hu H, et al. Design of therapeutic biomaterials
32. Frishman WH. A historical perspective on the development to control inflammation. Nat Rev Mater. 2022;7(7):557-574.
of β-adrenergic blockers. J Clin Hypertens. 2007;9(S4):19-27.
doi: 10.1038/s41578-022-00426-z
doi: 10.1111/j.1524-6175.2007.06633.x
44. Afify EA, Andijani NM. Potentiation of morphine-induced
33. Roozendaal B, Hahn EL, Nathan SV, de Quervain DJ, antinociception by propranolol: The involvement of
McGaugh JL. Glucocorticoid effects on memory dopamine and GABA systems. Front Pharmacol. 2017;8:794.
retrieval require concurrent noradrenergic activity in
the hippocampus and basolateral amygdala. J Neurosci. doi: 10.3389/fphar.2017.00794
2004;24(37):8161-8169. 45. Admani S, Feldstein S, Gonzalez EM, Friedlander SF.

Volume 11 Issue 4 (2025) 27 doi: 10.36922/JCTR025080010